<DOC>
	<DOCNO>NCT01222455</DOCNO>
	<brief_summary>A study evaluate amount fostamatinib blood subject impair hepatic ( liver ) function compare healthy volunteer normal liver function . The study also evaluate safety tolerability subject hepatic impairment .</brief_summary>
	<brief_title>A Study Fostamatinib Subjects With Impaired Hepatic ( Liver ) Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Males female ( non childbearing potential ) age 18 year , weight least 50 kg body mass index ( BMI ) 18 40 kg/m2 inclusive Healthy subject : good health determine medical history , physical examination , ECG clinical laboratory evaluation Healthy subject : negative result serum hepatitis B C Subjects receive medication know alter drug absorption elimination within 30 day first dose . Subjects smoke 10 cigarette equivalent per day Absolute neutrophil count &lt; 2500/mm3 Abnormal vital sign , additional systemic disease ( eg , cardiac , renal disease ) abnormal laboratory finding judge clinically significant investigator Healthy volunteer : use prescribe medication within 2 week first dose use nonprescribed medication within 1 week first dose Hepatic subject : fluctuate rapidly deteriorate hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Volunteers hepatic impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Fostamatinib</keyword>
</DOC>